OncoMark has been acquired by Cepheid!
Learn More »
OncoMark is focused on the development of novel panels of cancer biomarkers to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life for cancer patients.read more »
OncoMasTR is a novel prognostic test for early stage breast cancer. This gene expression profiling test accurately estimates the risk of recurrence for early-stage breast cancer patients. This test will aid the clinicians in determining the best treatment options for their patients. read more »
Gene expression profiling test for early-stage breast cancer prognosis